![]() |
市场调查报告书
商品编码
1519492
2024-2032 年按产品、应用、最终用户(製药和生物技术公司、学术和政府机构、合约研究组织)和地区分類的高内涵筛选市场报告High Content Screening Market Report by Product, Application, End-User (Pharmaceutical and Biotechnology Companies, Academic and Government Institutes, Contract Research Organizations ), and Region 2024-2032 |
2023 年,全球高内容放映市场IMARC Group达到 13 亿美元。全球高内涵筛选市场正在经历显着增长,其驱动因素包括透过使用整合成像技术、增加对药物研究的投资、在最大限度地减少时间和成本的同时对筛选方法的需求不断增加以及自动化系统的建立,药物发现应用的快速发展。
主要市场驱动因素:高内涵筛选市场的成长主要是由药物发现和开发需求不断增长、高通量生产成像技术的进步以及对製药和生物技术研究的大量投资分配所推动的。此外,对快速、高效的筛选技术的需求,有助于识别和理解活性候选药物,也促进了市场的成长。
主要市场趋势:市场趋势包括使用资料分析的人工智慧和机器学习演算法的快速数位化,结合产生更多生理相关结果的 3D 细胞模型,以及针对各种细胞模型的多范式分析的开发。
地理趋势:由于製药和生物技术行业的快速发展、持续的研发投资、先进的医疗基础设施(与市场主要参与者和学术研究机构的存在相关),北美在市场上占据主导地位。
竞争格局:该行业的一些主要市场参与者包括 Becton、Dickinson and Company、Bio-Rad Laboratories Inc.、Biotek Instruments Inc.、Danaher Corporation、GE Healthcare、Merck Millipore、Perkinelmer Inc.、Tecan Group Ltd.、Thermo Fisher Scientific、横河电机公司等。
挑战与机会:市场面临设备与试剂成本高、资料分析与标准复杂等挑战。另一方面,在开发新的创新成像技术或将其应用范围扩大到药物发现之外,以及使学术界和工业界之间的合作研究更容易研发方面,高内容筛选市场机会是巨大的。
该市场主要是由对快速有效的药物发现方法日益增长的需求所推动的。例如,NIH 报告称,预计到 2025 年,全球药品市场将几乎翻倍,达到 1.5 兆美元,因此迫切需要先进的筛选技术。 HCS 反过来又可以同时分析许多参数,并儘早识别潜在的候选药物,从而缩短开发时间。因此,製药组织被迫信任 HCS,从而扩大了研究市场规模并改善了药物的发现过程。
公司不断开发影像技术,有助于提供更准确、更详细、更专业的诊断工具,创造积极的高内涵筛检市场前景。例如,美国国家科学基金会 (NSF) 报告显示,年增长率为 6.2%,这意味着越来越多的实验室正在采用先进成像模式的操作,应用于细胞分析的高内涵筛选。研究人员现在可以透过超解析度显微镜、共焦成像和活细胞成像设备即时拍摄细胞结构和运作的高品质影像。这些技术创新使未来的高内涵筛选系统具有更好的分析精度和更详细的结果,从而使识别细胞过程和对刺激的反应的工作更加先进和彻底。因此,采用最新成像技术的更清洁、更有效率的高内容筛选系统的供应正在增加,这推动了市场的发展。
生技研究投资不断增加
由于世界各地对生物技术的投资不断增加,高内容筛选市场收入正经历显着成长。根据生物技术创新组织 (BIO) 的数据,2020 年全球生物技术研发支出超过 2,100 亿美元,显示了在推进科学知识以及开发新治疗方案方面的投资。高内涵筛选透过加速细胞功能和分子间相互作用的研究过程,在生物技术研究中占据核心地位。生物技术公司和研究机构利用新的发现目标进行药物开发、评估化合物的功效和毒性以及阐明疾病机制是推动高内涵筛选市场需求增加的一些因素。因此,这种趋势将导致市场成长,并将进行高内涵筛选技术的进一步研究。
IMARC Group提供了每个细分市场的主要趋势分析,以及 2024-2032 年全球、区域和国家层面的预测。我们的报告根据产品、应用和最终用户对市场进行了分类。
仪器
细胞成像和分析系统
流式细胞仪
耗材
试剂和检测试剂盒
微孔板
其他的
软体
服务
配件
仪器仪表占据大部分市场份额
该报告根据产品提供了详细的市场细分和分析。这包括仪器(细胞成像和分析系统以及流式细胞仪)、消耗品(试剂和检测试剂盒、微孔板等)、软体、服务和配件。报告称,仪器仪表占最大部分。
仪器透过确保精确有效的细胞分析来主导市场,从而促进药物的发现和研究。例如,NIH 预测,到 2025 年,全球研究设备和仪器的采购额将超过 530 亿美元。 因此,这种高额投资导致高内容生物医学研究对最新技术设备的需求不断增长。然而,主要的製药和生物技术公司已经引入了筛选平台技术,加速了药物发现过程,这将导致高内涵筛选仪器的巨大成长。因此,从事仪器製造的人们正在将注意力转向创造更现代化的工具,以提供更好的成像、自动化和资料分析功能,以满足不断寻找新事物的科学家的需求。
目标识别和验证
初级筛选和二级筛选
毒性研究
化合物分析
其他的
初筛、二次筛选行业份额最大
报告还提供了基于应用程式的详细市场细分和分析。这包括目标识别和验证、初级筛选和二级筛选、毒性研究、化合物分析等。报告称,初级筛选和二级筛选占了最大的市场份额。
由于加速药物发现过程的紧迫性日益增加,初级筛选和二级筛选在市场上占据主导地位。根据 NIH 的资料,全球製药业正在经历加速成长,预计 2024 年销售额将达到 1.2 兆美元。化合物库很快就变得自动化和系统化。随后,基于细胞的检测对于在二级筛选步骤中追踪命中化合物、表征其功效、安全性和作用机制是必不可少的。这加速了初级和二级高内容筛选解决方案的采用。
製药和生物技术公司
学术和政府机构
合约研究组织 (CRO)
製药和生物技术公司代表了领先的细分市场
该报告根据最终用户对市场进行了详细的细分和分析。这包括製药和生物技术公司、学术和政府机构以及合约研究组织 (CRO)。报告称,製药和生技公司占最大部分。
製药和生物技术公司的驱动力是加快市场领域药物发现或开发的基本需求。根据美国国立卫生研究院 (NIH) 的数据,到 2025 年,全球药品产业预计将超过 1.5 兆美元。此外,高内涵筛选使药物和生物技术公司能够进行深入的细胞测定,从而能够评估候选药物的有效性和副作用。透过使用高内涵筛选方法,这些公司基本上可以实现其研究工作流程的自动化,从而缩短开发时间,从而更快地将新疗法推向市场。此外,影像技术和资料分析演算法的进步增强了高内涵筛检平台发现未知生命行为和疾病机制的能力。因此,製药和生技公司在高内涵筛选开发方面的投资很高,从而带来了创新和病患治疗结果的改善。
北美洲
美国
加拿大
亚太地区
中国
日本
印度
韩国
澳洲
印尼
其他的
欧洲
德国
法国
英国
义大利
西班牙
俄罗斯
其他的
拉丁美洲
巴西
墨西哥
其他的
中东和非洲
北美市场领先,占据最大的高内容放映市场份额
该报告还对所有主要区域市场进行了全面分析,其中包括北美(美国和加拿大);亚太地区(中国、日本、印度、韩国、澳洲、印尼等);欧洲(德国、法国、英国、义大利、西班牙、俄罗斯等);拉丁美洲(巴西、墨西哥等);以及中东和非洲。报告称,北美是高内容放映的最大区域市场。
由于政府向生物医药产业提供大量补助,北美在市场上占据主导地位。例如,美国国立卫生研究院 (NIH) 报告称,美国政府每年的生物医学研究预算高达 300 亿美元。然而,这项巨额投资刺激了创新,从而加强了更先进筛选技术的使用,从而促进了市场的发展。此外,该地区拥有完善的医疗基础设施、领先的研究机构群和高水准的劳动力,这些都为该地区在高内涵筛检市场上赢得了额外的声誉。因此,北美在製药和生物领域的研发设备方面始终处于领先地位。
市场研究报告也对市场竞争格局进行了全面分析。也提供了所有主要公司的详细资料。高内涵筛检产业的一些主要市场参与者包括 Becton、Dickinson and Company、Bio-Rad Laboratories Inc.、Biotek Instruments Inc.、Danaher Corporation、GE Healthcare、Merck Millipore、Perkinelmer Inc.、Tecan Group Ltd.、Thermo费希尔科学公司和横河电机公司。
(请注意,这只是关键参与者的部分列表,报告中提供了完整列表。)
高内涵筛选市场企业正在投资产品的研发(R&D),以升级产品、拓宽市场。 Thermo Fisher Scientific、PerkinElmer 和 GE Healthcare 等引领了高内涵筛检影像技术的趋势。例如,赛默飞世尔科技 (Thermo Fisher Scientific) 2020 年在研发活动上花费了约 11 亿美元。这些投资旨在开发新的成像技术、自动化解决方案和软体平台,这些技术、自动化解决方案和软体平台能够推动不断增长的市场并满足对高级细胞分析和药物发现相关应用不断寻求的需求。这些企业正在开发具有增强成像、自动化功能和资料分析演算法的显微镜系统,以满足製药和生物技术科学家在药物开发和细胞分析实验中的新兴需求。
2022 年 9 月,BD(Becton、Dickinson and Company)宣布推出名为 BD Research Cloud 的基于云端的软体解决方案,旨在实现流式细胞仪工作流程的自动化。该计画的座右铭是协助免疫学、病毒学、肿瘤学和传染病控制等不同领域的科学家。虽然 BD 研究云的模组化和灵活方法透过缩短了解科学研究最需要的方面的时间来提高实验品质和上市时间,但 BD 研究云致力于增强这些领域的科学研究和创新。
2022年4月,Sysmex Europe推出了具有CE-IVD标誌的流式细胞仪XF-1600,以满足临床流式细胞仪实验室的需求。该系统提供强大而可靠的免疫表型分析能力,有助于精确表征细胞以用于诊断和研究目的。凭藉其先进的功能和监管批准,流式细胞仪 XF-1600 提高了临床实验室工作流程的效率和准确性,有助于改善患者护理和结果。
The global high content screening market size reached US$ 1.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.6 Billion by 2032, exhibiting a growth rate (CAGR) of 7.5% during 2024-2032. The global high content screening market is experiencing significant growth driven by rapid advancements in drug discovery applications through the use of integrated imaging technologies, heightening investments in pharmaceutical research, escalating demand for a screening method while minimizing time and cost, and the establishment of automated system in laboratories.
Major Market Drivers: The high content screening market growth is driven largely by the growing demand from drug discovery and development, progress in imaging technologies featuring high-throughput production, and large investments allocation to pharmaceuticals and biotechnology studies. Besides, the demand for expeditious and productive screening techniques, aiding the identification and understanding of active drug candidates, also adds fuel to the market growth.
Key Market Trends: The market trends include the rapid digitization of AI and machine learning algorithms that use data analysis, incorporating 3D cell models that produce more physiologically relevant results, and the development of multiparadigm assays for various cellular models.
Geographical Trends: North America dominate the market due to rapid development in the pharmaceutical and biotechnology industries, ongoing investments in research and development, advanced healthcare infrastructure which connects to the presence of market key players and academic research institutions.
Competitive Landscape: Some of the major market players in the industry include Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Biotek Instruments Inc., Danaher Corporation, GE Healthcare, Merck Millipore, Perkinelmer Inc., Tecan Group Ltd., Thermo Fisher Scientific, Yokogawa Electric Corporation, among many others.
Challenges and Opportunities: The market faces challenges such as the high cost of equipment and reagents, the complexity of data analysis and standards. On the other hand, high content screening market opportunities are enormous in terms of developing new innovative imaging technologies or broadening their range of applications beyond drug discovery and making collaborative studies between academia and industry easier for research and development.
The market is primarily driven by the increasing need for fast and effective drug discovery approaches. For instance, NIH reports that the global pharmaceutical market is anticipated to almost double and stand at 1.5 trillion dollars in 2025 thus urging for advanced screening technologies. HCS in turn enables the analyses of many parameters at the same time and the earlier identification of potential drug candidates, hence allowing shorter time to develop them. As a result, pharmaceutical organizations are forced to put their trust in HCSs which consequently makes the research market size larger and improves the discovery process of drugs.
The imaging technologies are continuously developed by companies, that help to provide more accurate, detailed, and specialized diagnostic tools, creating a positive high content screening market outlook. For instance, the National Science Foundation (NSF) report shows the annual growth of 6.2%, which means more and more laboratories are adopting the operatories of advanced imaging modalities for application in high content screening of cellular analysis. Researchers can now make high-quality images of the structures and workings of cells in real time via super-resolution microscopy, confocal imaging, and live-cell imaging facilities. Such technical innovations upgrade the high content screening systems with better analytical precision and more detailed results in the future, thus the work of identifying cellular processes and response to stimuli becomes more advanced and thorough. Hence, the supply of cleaner and more efficient high content screening systems, incorporating the latest imaging technics is rising which is responsible for the market development.
Rising Investments in Biotechnology Research
The high content screening market revenue is experiencing significant growth due to rising investments in biotechnology around the world. As per Biotechnology Innovation Organization (BIO), global spending on biotechnological R&D exceeded $210 billion in 2020 showing the investments made in advancing scientific knowledge as well as development of new therapeutic options. High content screening takes a central position in biotechnology research by speeding up the investigating process of wondering what the cells do and the interactions among the molecules. Biotech firms and research institutions utilizing new discovery targets for drug development, as well as assessing compound efficacy and toxicity, and elucidating disease mechanisms are some of the factors driving an increased high content screening market demand. As a result, this tendency will lead to market growth and further research on high content screening techniques will be done.
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product, application, and end-user.
Instruments
Cell Imaging and Analysis Systems
Flow Cytometers
Consumables
Reagents & Assay Kits
Microplates
Others
Software
Services
Accessories
Instruments accounts for the majority of the market share
The report has provided a detailed breakup and analysis of the market based on the product. This includes instruments (cell imaging and analysis systems and flow cytometers), consumables (reagents & assay kits, microplates, and others), software, services, and accessories. According to the report, instruments represented the largest segment.
Instruments dominate the market by assuring a precise and effective cellular analysis that leads to discovery of drugs and research. For instance, NIH projections forecast that the figures for worldwide purchases of the research equipment and instrumentation will pass $53 billion mark by 2025. This high magnitude investment thus accounts to the increasing demand for up-to-date technology equipment in biomedical research with high content screening instruments. However, major pharmaceutical and biotechnology firms have introduced screening platforms technologies in which drug discovery processes are accelerated that will lead to huge growth of high content screening instruments. As a result, those engaged in the manufacture of instruments are shifting their attention towards creating more modern tools that offer better imaging, automation, and data analysis features to satisfy the demand of scientists who are always looking for something new.
Target Identification and Validation
Primary Screening and Secondary Screening
Toxicity Studies
Compound Profiling
Others
Primary screening and secondary screening hold the largest share of the industry
A detailed breakup and analysis of the market based on the application have also been provided in the report. This includes target identification and validation, primary screening and secondary screening, toxicity studies, compound profiling, and others. According to the report, primary screening and secondary screening accounted for the largest market share.
Primary screening and secondary screening dominate the market due to the rising urgency of accelerating the drug discovery process. According to data from NIH, the global pharmaceutical industry is experiencing an accelerated growth and is expected to reach an estimate of $1,200 billion in sales in 2024. This is a leverage to invest in high content screening technologies for primary screening, as the ability to evaluate large amounts of compound libraries to identify potential drug candidates quickly becomes automated and systematic. Afterward, cell-based assays are indispensable for following up on hit compounds in the secondary screening step, characterizing their efficacy, safety, and mechanism of action. This accelerates primary and secondary high content screening solutions adoption.
Pharmaceutical and Biotechnology Companies
Academic and Government Institutes
Contract Research Organizations (CROs)
Pharmaceutical and biotechnology companies represent the leading market segment
The report has provided a detailed breakup and analysis of the market based on the end-user. This includes pharmaceutical and biotechnology companies, academic and government institutes, and contract research organizations (CROs). According to the report, pharmaceutical and biotechnology companies represented the largest segment.
Pharmaceutical and biotechnology firms are driven by the basic necessity to speed up drug discovery or development in the field of market. As per the National Institutes of Health (NIH), the global drugs industry is anticipated to go beyond 1.5 trillion dollars by the year 2025. This abundant market chance therefore entices firms to invest in the state-of-the-art screening technologies to screen drug candidates swiftly. Moreover, high-content screening allows drug and biotechnology companies to perform in-depth cellular assays, thus enabling the evaluation of drug candidates' effectiveness and side-effect profiles. With the use of high content screening methods, these companies can essentially automate their research workflow and therefore shorten development timelines to bring novel treatments to the market faster. Furthermore, progress in imaging technology and data analysis algorithms adds to the power of high content screening platforms to the discovery of unsuspected life behaviors and disease mechanisms. Thus, investments of pharmaceutical and biotechnology companies in the development of high content screening run high leading to innovation and improvement of patient outcome.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America leads the market, accounting for the largest high content screening market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for high content screening.
North America dominates the market due to the provision of massive government grant to biomedical industry. For instance, the National Institutes of Health or NIH reported that the US government covers up to $30 billion in its yearly budget for biomedical research. This sizeable incurred investment, however, stimulates innovation, therefore enhancing the use of more advanced screening technologies resulting in the market development. Further, the area enjoys well-established medicine infrastructure, a cluster of leading research institutes and a labor force with a high level of competence which provide additional prestige to the region in the high content screening market. As result North America stays at the forefront of the equipment used in the pharmaceutical and biological sectors' research and development.
The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the high content screening industry include Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Biotek Instruments Inc., Danaher Corporation, GE Healthcare, Merck Millipore, Perkinelmer Inc., Tecan Group Ltd., Thermo Fisher Scientific and Yokogawa Electric Corporation.
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
The high content screening market companies are investing in the research and development (R&D) of the product to upgrade the product and broaden the market. Thermo Fisher Scientific, PerkinElmer, and GE Healthcare, amongst others, leading the trend in imaging technologies for high-content screening. For instance, Thermo Fisher Scientific spent around 1.1 billion dollars in 2020 on R&D activities. These investments aim to develop new imaging technologies, automation solutions and software platforms that are capable of driving the growing market and meeting the ever-searching demand for advanced cellular analysis and drug discovery related applications. These businesses are developing microscopy systems with enhanced imaging, automation features, and data analysis algorithms that suit the emerging needs of pharmaceutical and biotechnology scientists in drug development and cellular analysis experiments.
In September 2022, BD (Becton, Dickinson and Company) announced the launch of a cloud-based software solution called BD Research Cloud intended to automate the flow cytometry workflow. The motto of the project is to assisting scientists in diverse fields, such as immunology, virology, oncology, and infectious diseases control. While the modular and flexible approach of the BD Research Cloud improves both the quality of the experiments and the time-to-market by fastening the time to insight most needed aspects of scientific investigations BD Research Cloud strives to augment scientific research and innovation in these areas.
In April 2022, Sysmex Europe launched the CE-IVD-marked Flow Cytometer XF-1600, catering to clinical flow cytometry laboratories. This system offers robust and reliable immunophenotyping capabilities, aiding in the precise characterization of cells for diagnostic and research purposes. With its advanced features and regulatory approval, the Flow Cytometer XF-1600 enhances efficiency and accuracy in clinical laboratory workflows, contributing to improved patient care and outcomes.